Categories
Pancreatic Cancer

EP. 362 #LIVECAST – CASEY AHERN – @Pancreatic Cancer Action Network (LIVE AND AMPLIFIED) [Video]

EP. 362 #LIVECAST – CASEY AHERN – @Pancreatic Cancer Action Network (LIVE AND AMPLIFIED)

If you can, please donate to our fundraiser for Pancreatic Cancer Research to benefit PanCAN: https://secure.pancan.org/site/TR?team_id=30962&fr_id=1081&pg=team

Check out the Live and Amplified Project at: https://www.facebook.com/liveNamplified/

Check out Casey Ahern: https://www.facebook.com/CaseyAhernMusic

We are a Music based Multi-Media Project, We feature independent musicians giving them the opportunity to showcase and talk about original content. Make sure you check out our Web series and Music Videos at:
https://www.youtube.com/user/bleacherbumstv

if you have any questions or comments please send them to
westoakstreetproductions@yahoo.com

Watch/Read More
Categories
Pancreatic Cancer

Local triathlete biking for pancreatic cancer research [Video]

Patricia Pedersen is a local who is embarking on an emotional journey this weekend. Called "Everesting", Patricia will be cycling up Sydenham Hill in Dundas Ontario up 90 times, which would be the equivalent of climbing the height of Mount Everest. For this eight-time ironman finisher, she thought it would be a great way to fundraise and raise awareness for pancreatic cancer in honour of her friend Lara who is battling this cancer. The following week (May 28), Patricia will embark on the 7 days in May week long 1,200km ride across Ontario. Melissa Candelaria spoke with Patricia on May 17, who starts off by going more in depth about why she's taking on these two major challenges. For details and to donate go to https://bit.ly/37VqH5W.

Categories
Pancreatic Cancer

CodeBreak100: assessing sotorasib in patients with KRAS p.G12C-mutant pancreatic cancer [Video]

KRAS mutations are present in 90% of pancreatic ductal adenocarcinomas (PDACs). P.G12C accounts for 1-2% of these KRAS mutations. John H. Strickler, MD, Duke Cancer Institute, Durham, NC, provides an overview of the international, single-arm, Phase I/II trial, CodeBreak100 (NCT03600883) exploring the KRAS p.G12C inhibitor, sotorasib, in patients with previosuly treated pancreatic cancer harboring the KRAS p.G12C mutation. The primary endpoint is confirmed objective response rate (ORR) and secondary endpoints include duration of response (DoR), progression-free survival (PFS) and overall-survival (OS). 38 patients with pancreatic cancer received sotorasib once daily. ORR was 21.1% and DCR was 84.2%, with a PFS of 4 months and median DoR of 6 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Pancreatic Cancer

Daytime Columbus Pancreatic Cancer Action Network 6 13 14 Facebook [Video]

Jami Oliver, CEO of Oliver Law Office in Dublin, Ohio is a guest on Daytime Columbus in 2014 discussing pancreatic cancer research and advocacy in her role as Chair of the Advocacy Section of the Columbus, Ohio Affiliate for PanCan, a national charitable organization with whom she has volunteered her skills and her time.